With more than 25 years of experience in early stage research, Pharm-Olam understands just how critical your early decisions are. As your partner, we deploy our network of seasoned, early-phase investigators to ensure that your Phase I clinical trial is maximized for success.
From project management to data management and from site feasibility to pharmacokinetics, our experts are ready to help you work through the specific challenges posed by early stage research. Our attention to detail helps ensure that your studies start fast and that you have the information you need to make those critical decisions and reassure all your stakeholders. And, with a global presence in more than 60 countries, we can identify appropriate sites wherever your study takes you.
Our deep expertise in Phase I research includes studies for:
First in human
Single ascending dose (SAD), multiple ascending dose (MAD)
Human absorption, metabolism, and excretion (AME)
Health normal volunteers
Full-Service Capabilities to Support Early Phase Research
Your study is unique, which is why we offer a complete suite of customizable services to support your research in a full-service or functional provider setting. With Pharm-Olam as your partner, you can be assured you will have the support you need for your study’s unique requirements. We have strong working relationships with Phase I investigators and units around the globe, and we are committed to ensuring high-quality data and adherence to all good clinical practices and regulations.
Put Our Therapeutic Experts to Work on Your Challenges
Pharm-Olam has strategically invested in our therapeutic areas to provide aligned and experienced teams, sites and supporting vendors; all of which are optimized to deliver your study effectively and on time. You can expect true expertise and innovative strategies from our team. We focus in the following areas:
Rare Disease Center of Excellence – A recognized leader in rare disease research: We’ve conducted more than 100 rare disease studies and bring unique solutions to their unique challenges.
Infectious Disease & Vaccines Center of Excellence – Our track record in this therapeutic area is a long one: We have supported the development of more than half of all antibiotics approved by FDA/EMA since 2010, and have strong and current experience in various emerging and re-emerging infectious diseases.
General Medicine – Supporting an additional 13 therapeutic areas, with recent and relevant experience to support your next clinical trial.
We Make Delivery Excellence Our Pattern
The Pattern of Excellence was created to provide our clients with a definitive customer experience that adds true value to the clinical trial and relationship between Sponsor and CRO. Pharm-Olam wants to partner with you to create a healthier world. We are here for the patients, the research and for you, to help you on this journey.